Tisagenlecleucel CAR-T for relapsed/refractory diffuse large B-cell lymphoma, one therapy; two different clinical presentations. An urgent need to design adverse event predictors

Tomasik, Jaromir; Drozd‐Sokołowska, Joanna; Kacprzyk, Piotr; Tomaszewska, Agnieszka; Machowicz, Rafał; Urbanowska, Elżbieta; Witkowska, Samanta; Basak, Grzegorz

doi:10.5603/ahp.a2023.2018

Acta Haematol Pol.

2023

DOI: 10.5603/ahp.a2023.2018

|View full text |Cite

Tisagenlecleucel CAR-T for relapsed/refractory diffuse large B-cell lymphoma, one therapy; two different clinical presentations. An urgent need to design adverse event predictors

Jaromir Tomasik¹,

Joanna Drozd‐Sokołowska²,

Piotr Kacprzyk³

et al.

Abstract: This article has been peer reviewed and published immediately upon acceptance.It is an open access article, which means that it can be downloaded, printed, and distributed freely, provided the work is properly cited.

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...

Citation Types

Supporting

Mentioning

Contrasting

Year Published

2024

Publication Types

Select...

Article1

Relationship

Self Cite0

Independent1

Authors

Journals

Cited by 1 publication

References 5 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

Endothelial Activation and Stress Index Score as a Prognostic Factor of Cytokine Release Syndrome in CAR-T Patients – A Retrospective Analysis of Multiple Myeloma and Large B-Cell Lymphoma Cohorts

Tomasik,

Avni,

Grisariu

et al. 2024

Archivum Immunologiae Et Therapiae Experimentalis

View full text Add to dashboard Cite

Endothelial Activation and Stress Index (EASIX) has been proposed as a prognostic factor of adverse events or survival in hematological malignancies. Endothelial dysfunction has been associated with complications following stem cell transplantation and chimeric antigen receptor (CAR)-T therapy. This retrospective cohort study evaluated the utility of the EASIX score as a prognostic factor of cytokine release syndrome (CRS) in multiple myeloma/light-chain amyloidosis (MM/AL amyloidosis; N = 69) and large B-cell lymphoma (LBCL) cohorts (N = 65). Occurrence of CRS grade ≥3 was the primary endpoint. For both cohorts, the EASIX and simplified EASIX (s-EASIX) scores were calculated at four different time points before CAR-T infusion to assess its prognostic value. In the MM/AL amyloidosis cohort, neither EASIX nor s-EASIX scores calculated at any time point were associated with the occurrence of CRS grade ≥3. In the LBCL cohort, EASIX and s-EASIX scores measured before lymphodepletion (EASIX-pre and s-EASIX-pre) showed a significant relationship with CRS grade ≥3 (odds ratio [OR] = 1.06 and OR = 1.05, respectively). The cutoff value of 1.835 for EASIX-pre was associated with 4.59-fold increased OR of CRS grade ≥3 (95% confidence interval [CI]: 1.13–21.84), whereas s-EASIX-pre cutoff equaled 2.134 and was associated with 4.13-fold increased OR of CRS grade ≥3 (95% CI: 1.01–17.93). However, after internal validation with bootstrapping, the significance was lost both for the EASIX-pre and s-EASIX-pre cutoff. The presented findings indicate that the EASIX scores fail to predict CRS in MM/amyloidosis CAR-T patients, whereas they can be implemented as CRS grade ≥3 predictors in LBCL CAR-T patients.

show abstract

Endothelial Activation and Stress Index Score as a Prognostic Factor of Cytokine Release Syndrome in CAR-T Patients – A Retrospective Analysis of Multiple Myeloma and Large B-Cell Lymphoma Cohorts

Tomasik,

Avni,

Grisariu

et al. 2024

Archivum Immunologiae Et Therapiae Experimentalis

View full text Add to dashboard Cite

show abstract

scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.

Contact Info

customersupport@researchsolutions.com

10624 S. Eastern Ave., Ste. A-614

Henderson, NV 89052, USA

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Blog Terms and Conditions API Terms Privacy Policy Contact Cookie Preferences Do Not Sell or Share My Personal Information

Made with 💙 for researchers

Part of the Research Solutions Family.

Tisagenlecleucel CAR-T for relapsed/refractory diffuse large B-cell lymphoma, one therapy; two different clinical presentations. An urgent need to design adverse event predictors

Abstract: This article has been peer reviewed and published immediately upon acceptance.It is an open access article, which means that it can be downloaded, printed, and distributed freely, provided the work is properly cited.

Cited by 1 publication

References 5 publications

Endothelial Activation and Stress Index Score as a Prognostic Factor of Cytokine Release Syndrome in CAR-T Patients – A Retrospective Analysis of Multiple Myeloma and Large B-Cell Lymphoma Cohorts

Endothelial Activation and Stress Index Score as a Prognostic Factor of Cytokine Release Syndrome in CAR-T Patients – A Retrospective Analysis of Multiple Myeloma and Large B-Cell Lymphoma Cohorts

Contact Info

Product

Resources

About